Health Care

Insider buying at Tenax Therapeutics signals confidence in its PH‑HFpEF levosimendan pipeline—explore why executives see long‑term upside despite current losses.

Palaisade Bio insider buy signals confidence in its Phase III Crohn’s drug; watch for FDA filing and market launch in 2026.

Broadwood’s steady buying of STAAR Surgical shares signals confidence in its safe, FDA‑cleared EDOF lenses—backed by strong 88% success rates—and a projected $650 million U.S. cataract implant revenue in 2027–29, making STAAR a top contender for inv…

Spyre Therapeutics’ new executive option grants signal confidence and long‑term commitment to its IBD antibody pipeline, highlighting potential upside and investor interest.

Arcellx insider trading recap: CMO Heery Christopher’s RSU vesting and tax‑sell moves reveal routine liquidity steps, not speculative bets, while positive sentiment and a 7.6% weekly surge hint at investor confidence in the biotech’s Phase II pipeli…

Insider buy signals confidence in Tenax Therapeutics’ levosimendan‑based pulmonary hypertension drug, highlighting Phase 3 readiness and FDA‑approved IND milestones.

Insider buying at Tenax Therapeutics signals confidence amid volatility, hinting a Phase‑3 data boost could lift stock—learn why it matters.

Mineralys Therapeutics insider trading shows strategic buying low, selling high—yet investors must weigh volatile stock, negative earnings, and pending regulatory approvals.

Insider June Sherie’s purchase of 30,000 zero‑exercise options highlights confidence in Tenax Therapeutics’ levosimendan pulmonary‑hypertension pipeline, suggesting a potential valuation boost once clinical milestones arrive.

Praxis Precision Medicines insider sales show routine tax‑related moves, not distress, while the company eyes FDA approvals that could boost its value.